Home » Stocks » Equillium

Equillium, Inc. (EQ)

Stock Price: $10.11 USD 0.06 (0.60%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
Pre-market: $9.82 -0.29 (-2.87%) Aug 12, 8:13 AM

Stock Price Chart

Key Info

Market Cap 178.79M
Revenue (ttm) n/a
Net Income (ttm) -27.49M
Shares Out 17.68M
EPS (ttm) -1.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $10.11
Previous Close $10.05
Change ($) 0.06
Change (%) 0.60%
Day's Open -
Day's Range 10.02 - 12.29
Day's Volume 1,346,065
52-Week Range 2.20 - 27.05

More Stats

Market Cap 178.79M
Enterprise Value 140.86M
Earnings Date (est) Aug 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 17.68M
Float 6.59M
EPS (basic) -1.58
EPS (diluted) -1.58
FCF / Share -1.42
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 11,308
Short Ratio 0.13
Short % of Float 20.27%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 4.61
Revenue n/a
Operating Income -27.83M
Net Income -27.49M
Free Cash Flow -24.93M
Net Cash 37.93M
Net Cash / Share 2.14
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -30.89%
ROE -57.36%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

(85.46% upside)
Current: $10.11
Target: 18.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-26.73-8.62
Net Income-25.60-13.25
Shares Outstanding17.3812.19
Earnings Per Share-1.47-1.09
Operating Cash Flow-22.95-7.53
Capital Expenditures-0.07-0.04
Free Cash Flow-23.02-7.56
Cash & Equivalents53.1465.91
Total Debt9.68-
Net Cash / Debt43.4665.91
Book Value41.8564.94
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Equillium, Inc.
Country United States
Employees 22
CEO Bruce D. Steel

Stock Information

Ticker Symbol EQ
Stock Exchange NASDAQ
Unique Identifier NASDAQ: EQ
IPO Date October 11, 2018


Equillium, Inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in La Jolla, California.